Sprint Bioscience AB (publ) reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was SEK 0.045 million compared to SEK 0.035 million a year ago. Revenue was SEK 0.053 million compared to SEK 0.408 million a year ago. Net loss was SEK 14.21 million compared to SEK 13.7 million a year ago. Basic loss per share from continuing operations was SEK 0.36 compared to SEK 0.64 a year ago.